Haisco Pharmaceutical Group Co. Ltd. Class A 002653
SZSE · China · Health Technology
CNY 62.18+0.25 (+0.40%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
Phase 2b dose ranging data presented at ERS show both doses of AN01 delivered significant and clinically relevant improvements in lung function versus placebo at Week 4Trial comprised of broad COPD population, including participants on background single or dual bronchodilator therapy AN01 was well tolerated with no treatment-related adverse events reported in the 0.75 mg dose group, the dose under investigation in the Phase 3 program AirNexis has completed its Phase 1 multiple ascending dose (MA
On August 25, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners ("PHP") and ARCH Venture Partners ("ARCH"), to grant Sentivera the rights to develop, manufacture, and commercialize its independently developed one pre-clinical innovative drug globally, excluding Greater China.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.